Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Colorcon
Express Scripts
Mallinckrodt
Healthtrust
Federal Trade Commission
Deloitte
Daiichi Sankyo
McKesson

Generated: June 18, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR CHENODIOL

« Back to Dashboard

Clinical Trials for CHENODIOL

Trial ID Title Status Sponsor Phase Summary
NCT00912301 Cheno Effect on Transit in Health and IBS-C Completed National Center for Research Resources (NCRR) Phase 2 The study hypothesis is that the naturally occurring bile acid, chenodeoxycholic acid, induces acceleration of colonic transit in health and in patients with constipation-predominant Irritable Bowel Syndrome (IBS-C).
NCT00912301 Cheno Effect on Transit in Health and IBS-C Completed National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Phase 2 The study hypothesis is that the naturally occurring bile acid, chenodeoxycholic acid, induces acceleration of colonic transit in health and in patients with constipation-predominant Irritable Bowel Syndrome (IBS-C).
NCT00912301 Cheno Effect on Transit in Health and IBS-C Completed Mayo Clinic Phase 2 The study hypothesis is that the naturally occurring bile acid, chenodeoxycholic acid, induces acceleration of colonic transit in health and in patients with constipation-predominant Irritable Bowel Syndrome (IBS-C).
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Clinical Trial Conditions for CHENODIOL

Condition Name

Condition Name for CHENODIOL
Intervention Trials
Constipation-predominant Irritable Bowel Syndrome 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for CHENODIOL
Intervention Trials
Constipation 1
Syndrome 1
Irritable Bowel Syndrome 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for CHENODIOL

Trials by Country

Trials by Country for CHENODIOL
Location Trials
United States 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for CHENODIOL
Location Trials
Minnesota 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for CHENODIOL

Clinical Trial Phase

Clinical Trial Phase for CHENODIOL
Clinical Trial Phase Trials
Phase 2 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for CHENODIOL
Clinical Trial Phase Trials
Completed 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for CHENODIOL

Sponsor Name

Sponsor Name for CHENODIOL
Sponsor Trials
National Center for Research Resources (NCRR) 1
Mayo Clinic 1
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for CHENODIOL
Sponsor Trials
NIH 2
Other 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
Johnson and Johnson
Harvard Business School
Merck
Citi
QuintilesIMS
Deloitte
Daiichi Sankyo
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.